Stock JENBURPH6 JENBURKT PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jenburkt Pharmaceuticals Limited

Equities

JENBURPH6

INE354A01013

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:30:57 04/07/2024 pm IST 		5-day change 1st Jan Change
878.4 INR -0.02% Intraday chart for Jenburkt Pharmaceuticals Limited +1.53% +29.15%
28/05 Jenburkt Pharmaceuticals Limited Announces Board Retirements CI
28/05 Jenburkt Pharmaceuticals Limited Announces Dividend CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,808 2,319 1,459 1,828 2,601 2,939
Enterprise Value (EV) 1 2,399 1,870 965 1,359 2,202 2,474
P/E ratio 16.3 x 11.7 x 9.81 x 11.1 x 11.7 x 11.9 x
Yield 1.47% 2.02% 2.55% 2.56% 2.12% 2.16%
Capitalization / Revenue 2.45 x 1.89 x 1.23 x 1.67 x 2.1 x 2.15 x
EV / Revenue 2.09 x 1.52 x 0.81 x 1.24 x 1.78 x 1.81 x
EV / EBITDA 10.1 x 7.49 x 5.16 x 7.13 x 8.24 x 8.28 x
EV / FCF 16.1 x 62.4 x 8.37 x 8.16 x 15.4 x 18.9 x
FCF Yield 6.22% 1.6% 11.9% 12.3% 6.51% 5.3%
Price to Book 4.58 x 2.99 x 1.82 x 1.86 x 2.22 x 2.4 x
Nbr of stocks (in thousands) 4,589 4,589 4,589 4,589 4,589 4,413
Reference price 2 611.9 505.2 317.8 398.4 566.6 666.0
Announcement Date 02/07/18 24/06/19 04/08/20 01/08/21 02/07/22 30/06/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 1,147 1,226 1,189 1,093 1,240 1,367
EBITDA 1 238 249.6 187 190.5 267.1 298.9
EBIT 1 223.3 236.2 174.5 178.1 254.4 281.9
Operating Margin 19.47% 19.26% 14.67% 16.29% 20.52% 20.61%
Earnings before Tax (EBT) 1 252.7 266.3 211.4 216.4 298.7 328.6
Net income 1 172.1 198 148.7 165 223 246.1
Net margin 15.01% 16.14% 12.51% 15.1% 17.98% 17.99%
EPS 2 37.50 43.14 32.40 35.96 48.58 55.76
Free Cash Flow 1 149.2 29.98 115.2 166.5 143.3 131.2
FCF margin 13.01% 2.44% 9.69% 15.24% 11.56% 9.59%
FCF Conversion (EBITDA) 62.68% 12.01% 61.62% 87.43% 53.66% 43.88%
FCF Conversion (Net income) 86.69% 15.14% 77.5% 100.92% 64.29% 53.3%
Dividend per Share 2 9.000 10.20 8.100 10.20 12.00 14.40
Announcement Date 02/07/18 24/06/19 04/08/20 01/08/21 02/07/22 30/06/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 409 449 494 469 398 466
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 149 30 115 167 143 131
ROE (net income / shareholders' equity) 29.8% 28.5% 18.9% 18.5% 20.7% 20.5%
ROA (Net income/ Total Assets) 18.1% 16.4% 10.5% 9.91% 12% 12.4%
Assets 1 948.8 1,209 1,411 1,666 1,852 1,989
Book Value Per Share 2 133.0 169.0 174.0 215.0 256.0 277.0
Cash Flow per Share 2 2.580 2.670 5.520 5.430 11.00 8.290
Capex 1 4.54 24 45.5 11.5 30.5 21
Capex / Sales 0.4% 1.96% 3.83% 1.05% 2.46% 1.54%
Announcement Date 02/07/18 24/06/19 04/08/20 01/08/21 02/07/22 30/06/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JENBURKT PHARMACEUTICALS LIMITED Stock Jenburkt Pharmaceuticals Limited
+29.15% 4.64Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.07% 81TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.01% 62TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.05% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.44% 32TCr
ABBVIE INC. Stock AbbVie Inc.
+5.72% 29TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.70% 24TCr
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 22TCr
NOVARTIS AG Stock Novartis AG
+14.42% 22TCr
AMGEN INC. Stock Amgen Inc.
+7.42% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JENBURPH6 Stock
  4. Financials Jenburkt Pharmaceuticals Limited